Efficacy and safety of nab-paclitaxel chemotherapy for patients with gastric carcinoma: A systematic review and single arm meta-analysis
Aim: This study aims to investigate the efficacy of nab-paclitaxel mono-chemotherapy as a second-line treatment for previously treated adenocarcinoma patients. Methods: We conducted a systematic review and meta-analysis of prospective single-arm clinical studies that tested nab-paclitaxel monotherap...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
KeAi Communications Co., Ltd.
2024-01-01
|
| Series: | Gastroenterology & Endoscopy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2949752324000025 |
| _version_ | 1797235397909020672 |
|---|---|
| author | Alyaa Khaled Madeeh Hossam Khaled Farouk Mohamed Mohamed Belal Sara Ramadan Batool Emad Al-Masri Mohamed Samier Salama Ahmed Gadallah Naseba Khapoli Abdulqadir J. Nashwan Yossef Hassan AbdelQadir |
| author_facet | Alyaa Khaled Madeeh Hossam Khaled Farouk Mohamed Mohamed Belal Sara Ramadan Batool Emad Al-Masri Mohamed Samier Salama Ahmed Gadallah Naseba Khapoli Abdulqadir J. Nashwan Yossef Hassan AbdelQadir |
| author_sort | Alyaa Khaled Madeeh |
| collection | DOAJ |
| description | Aim: This study aims to investigate the efficacy of nab-paclitaxel mono-chemotherapy as a second-line treatment for previously treated adenocarcinoma patients. Methods: We conducted a systematic review and meta-analysis of prospective single-arm clinical studies that tested nab-paclitaxel monotherapy for treating gastric carcinoma. The review was conducted in accordance with PRISMA. Results: We included 6 studies with a total of 271 patients. The pooled analysis of response rate, overall survival, and progression-free survival were 0.21 (95% CI: [0.16,0.28]), 11.65 (95% CI: [10.56, 12.75]), and 2.983 (95% CI: [2.625, 3.342]), respectively. There was no statistically significant difference between the doses regarding response rate and progression-free survival. However, the overall survival of the 150 mg/m2 dose was statistically significantly higher than the 260 mg/m2 dose. The treatment was associated with manageable toxicity profiles. Conclusion: Nab-paclitaxel mono-chemotherapy is an effective treatment option for previously treated and recurrent gastric cancer with a manageable toxicity profile. Future studies should aim to compare Nab-paclitaxel to other agents in direct head-to-head comparison. |
| first_indexed | 2024-04-24T16:47:19Z |
| format | Article |
| id | doaj.art-6599ee035f564212a90943bd8127c3be |
| institution | Directory Open Access Journal |
| issn | 2949-7523 |
| language | English |
| last_indexed | 2024-04-24T16:47:19Z |
| publishDate | 2024-01-01 |
| publisher | KeAi Communications Co., Ltd. |
| record_format | Article |
| series | Gastroenterology & Endoscopy |
| spelling | doaj.art-6599ee035f564212a90943bd8127c3be2024-03-29T05:52:00ZengKeAi Communications Co., Ltd.Gastroenterology & Endoscopy2949-75232024-01-01212537Efficacy and safety of nab-paclitaxel chemotherapy for patients with gastric carcinoma: A systematic review and single arm meta-analysisAlyaa Khaled Madeeh0Hossam Khaled Farouk1Mohamed Mohamed Belal2Sara Ramadan3Batool Emad Al-Masri4Mohamed Samier5Salama Ahmed Gadallah6Naseba Khapoli7Abdulqadir J. Nashwan8Yossef Hassan AbdelQadir9Faculty of Medicine, Fayoum University, Fayoum, EgyptFaculty of Medicine, Fayoum University, Fayoum, EgyptFaculty of Medicine, Alexandria University, Alexandria, EgyptFaculty of Medicine, Alexandria University, Alexandria, EgyptFaculty of Medicine, The University of Jordan, Amman, JordanFaculty of Medicine, Al-Azher University, Cairo, EgyptNew Damietta Faculty of Medicine, Al-Azher University, EgyptUniversity of Zawia, Faculty of Medicine, LibyaDepartment of Nursing, Hamad Medical Corporation, P.O. Box 3050 Doha, Qatar; Corresponding author.Faculty of Medicine, Alexandria University, Alexandria, EgyptAim: This study aims to investigate the efficacy of nab-paclitaxel mono-chemotherapy as a second-line treatment for previously treated adenocarcinoma patients. Methods: We conducted a systematic review and meta-analysis of prospective single-arm clinical studies that tested nab-paclitaxel monotherapy for treating gastric carcinoma. The review was conducted in accordance with PRISMA. Results: We included 6 studies with a total of 271 patients. The pooled analysis of response rate, overall survival, and progression-free survival were 0.21 (95% CI: [0.16,0.28]), 11.65 (95% CI: [10.56, 12.75]), and 2.983 (95% CI: [2.625, 3.342]), respectively. There was no statistically significant difference between the doses regarding response rate and progression-free survival. However, the overall survival of the 150 mg/m2 dose was statistically significantly higher than the 260 mg/m2 dose. The treatment was associated with manageable toxicity profiles. Conclusion: Nab-paclitaxel mono-chemotherapy is an effective treatment option for previously treated and recurrent gastric cancer with a manageable toxicity profile. Future studies should aim to compare Nab-paclitaxel to other agents in direct head-to-head comparison.http://www.sciencedirect.com/science/article/pii/S2949752324000025Nab-paclitaxelGastric adenocarcinomaNab toxicitySurvival improvementSingle arm meta-analysis |
| spellingShingle | Alyaa Khaled Madeeh Hossam Khaled Farouk Mohamed Mohamed Belal Sara Ramadan Batool Emad Al-Masri Mohamed Samier Salama Ahmed Gadallah Naseba Khapoli Abdulqadir J. Nashwan Yossef Hassan AbdelQadir Efficacy and safety of nab-paclitaxel chemotherapy for patients with gastric carcinoma: A systematic review and single arm meta-analysis Gastroenterology & Endoscopy Nab-paclitaxel Gastric adenocarcinoma Nab toxicity Survival improvement Single arm meta-analysis |
| title | Efficacy and safety of nab-paclitaxel chemotherapy for patients with gastric carcinoma: A systematic review and single arm meta-analysis |
| title_full | Efficacy and safety of nab-paclitaxel chemotherapy for patients with gastric carcinoma: A systematic review and single arm meta-analysis |
| title_fullStr | Efficacy and safety of nab-paclitaxel chemotherapy for patients with gastric carcinoma: A systematic review and single arm meta-analysis |
| title_full_unstemmed | Efficacy and safety of nab-paclitaxel chemotherapy for patients with gastric carcinoma: A systematic review and single arm meta-analysis |
| title_short | Efficacy and safety of nab-paclitaxel chemotherapy for patients with gastric carcinoma: A systematic review and single arm meta-analysis |
| title_sort | efficacy and safety of nab paclitaxel chemotherapy for patients with gastric carcinoma a systematic review and single arm meta analysis |
| topic | Nab-paclitaxel Gastric adenocarcinoma Nab toxicity Survival improvement Single arm meta-analysis |
| url | http://www.sciencedirect.com/science/article/pii/S2949752324000025 |
| work_keys_str_mv | AT alyaakhaledmadeeh efficacyandsafetyofnabpaclitaxelchemotherapyforpatientswithgastriccarcinomaasystematicreviewandsinglearmmetaanalysis AT hossamkhaledfarouk efficacyandsafetyofnabpaclitaxelchemotherapyforpatientswithgastriccarcinomaasystematicreviewandsinglearmmetaanalysis AT mohamedmohamedbelal efficacyandsafetyofnabpaclitaxelchemotherapyforpatientswithgastriccarcinomaasystematicreviewandsinglearmmetaanalysis AT sararamadan efficacyandsafetyofnabpaclitaxelchemotherapyforpatientswithgastriccarcinomaasystematicreviewandsinglearmmetaanalysis AT batoolemadalmasri efficacyandsafetyofnabpaclitaxelchemotherapyforpatientswithgastriccarcinomaasystematicreviewandsinglearmmetaanalysis AT mohamedsamier efficacyandsafetyofnabpaclitaxelchemotherapyforpatientswithgastriccarcinomaasystematicreviewandsinglearmmetaanalysis AT salamaahmedgadallah efficacyandsafetyofnabpaclitaxelchemotherapyforpatientswithgastriccarcinomaasystematicreviewandsinglearmmetaanalysis AT nasebakhapoli efficacyandsafetyofnabpaclitaxelchemotherapyforpatientswithgastriccarcinomaasystematicreviewandsinglearmmetaanalysis AT abdulqadirjnashwan efficacyandsafetyofnabpaclitaxelchemotherapyforpatientswithgastriccarcinomaasystematicreviewandsinglearmmetaanalysis AT yossefhassanabdelqadir efficacyandsafetyofnabpaclitaxelchemotherapyforpatientswithgastriccarcinomaasystematicreviewandsinglearmmetaanalysis |